Literature DB >> 2125585

Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study.

J P Kuebler1, P J Goodman, T D Brown, E D Crawford, C L Reitz, W A Knight, J A Kish.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2125585     DOI: 10.1007/bf00171843

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  6 in total

Review 1.  The role of biological response modifiers in metastatic renal cell carcinoma.

Authors:  H B Muss
Journal:  Semin Oncol       Date:  1988-10       Impact factor: 4.929

2.  Immune interferon activates cells more slowly than does virus-induced interferon.

Authors:  F Dianzani; L Salter; W R Fleischmann; M Zucca
Journal:  Proc Soc Exp Biol Med       Date:  1978-10

3.  Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma.

Authors: 
Journal:  Cancer       Date:  1987-09-01       Impact factor: 6.860

4.  A phase I clinical trial of recombinant DNA gamma interferon.

Authors:  T D Brown; J Koeller; K Beougher; J Golando; E M Bonnem; R J Spiegel; D D Von Hoff
Journal:  J Clin Oncol       Date:  1987-05       Impact factor: 44.544

5.  Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma.

Authors:  J R Quesada; R Kurzrock; S A Sherwin; J U Gutterman
Journal:  J Biol Response Mod       Date:  1987-02

6.  Phase I/II study of recombinant interferon gamma in advanced renal cell carcinoma.

Authors:  M B Garnick; S D Reich; B Maxwell; S Coval-Goldsmith; J P Richie; S A Rudnick
Journal:  J Urol       Date:  1988-02       Impact factor: 7.450

  6 in total
  1 in total

1.  Hemophagocytosis causes a consumptive anemia of inflammation.

Authors:  Erin E Zoller; Jennifer E Lykens; Catherine E Terrell; Julio Aliberti; Alexandra H Filipovich; Peter M Henson; Michael B Jordan
Journal:  J Exp Med       Date:  2011-05-30       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.